The FDA has approved dinutuximab (Unituxin, United Therapeutics), in combination with granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), to treat children with high-risk neuroblastoma who are partial responders to previous chemotherapy.

The recommended dose and schedule for dinutuximab is 17.5 mg/m² per day as a diluted IV infusion over 10 to 20 hours for four consecutive days for up to five cycles. Patients require IV treatment with opioids before, during and for two hours after the dinutuximab infusion to mitigate neuropathic pain. Patients also require prehydration and premedication to decrease the risk for hypotension and serious infusion reactions.

Dinutuximab is a monoclonal antibody containing a combination of mouse and human DNA.